I am a statistical epidemiologist at the Bennett Institute for Applied Data Science, interested in improving how routinely-collected health data can be used for prediction and inference, and improving research transparency and reusability in sensitive data settings.
I lead the Bennett Institute’s Epidemiology team, and co-lead the OpenSAFELY COVID-19 Vaccine Effectiveness Working Group.
My recent work has focused on target trial emulation and its use for vaccine effectiveness estimation.
Papers by Will Hulme
- Primary care coding activity related to the use of online consultation systems or remote consulting
- Consistency, completeness and external validity of ethnicity recording in NHS primary care records: a cohort study in 25 million patients’ records at source using OpenSAFELY
- Effectiveness of mRNA COVID-19 Vaccines as First Booster Doses in England
- Changes in opioid prescribing during the COVID-19 pandemic in England
- Trends in weight gain recorded in English primary care before and during the Coronavirus-19 pandemic: An observational cohort study using the OpenSAFELY platform
- OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents
- Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults
- The impact of the COVID-19 pandemic on Antidepressant Prescribing with a focus on people with learning disability and autism
- Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)
- The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate
- The impact of COVID-19 on medication reviews in English primary care
- Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England
- Measuring BMI in 22 million patients in England
- Weight trends amongst adults with diabetes or hypertension during the COVID-19 pandemic
- OpenSAFELY: a platform for analysing electronic health records designed for reproducible research
- Trends in inequalities in avoidable hospitalisations across the COVID-19 pandemic
- Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home
- Effect of the 2022 COVID-19 booster vaccination campaign in 50 year olds in England
- Challenges in Estimating the Effectiveness of 2 Doses of COVID-19 Vaccine Beyond 6 Months in England
- Eleven key measures for monitoring general practice clinical activity during COVID-19
- Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY
- Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages
- Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
- Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022
- Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England
- First dose COVID-19 vaccine coverage amongst adolescents and children in England
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings
- OpenSAFELY NHS Service Restoration Observatory 2
- Factors associated with COVID-19 vaccine uptake in people with kidney disease
- Comparative effectiveness of two- and three-dose schedules involving AZD1222 and BNT162b2 in people with kidney disease
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community
- Recording of ‘COVID-19 vaccine declined’
- Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose
- Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England
- Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England
- Association between oral anticoagulants and COVID-19-related outcomes
- Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies
- Safety of COVID-19 vaccination and acute neurological events
- Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta
- Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England
- Comparison of methods for predicting COVID-19-related death in the general population using the OpenSAFELY platform
- Potentially inappropriate prescribing of DOACs to people with mechanical heart valves
- Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation
- Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic
- OpenSAFELY NHS Service Restoration Observatory 1: primary care clinical activity in England during the first wave of COVID-19
- Trends and clinical characteristics of COVID-19 vaccine recipients
- Impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
- Clinical coding of long COVID in English primary care
- Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants
- Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England
- Risks of covid-19 hospital admission and death for people with learning disability
- Factors associated with deaths due to COVID-19 versus other causes
- Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England
- Identifying Care Home Residents in Electronic Health Records
- Association between living with children and outcomes from covid-19
- Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7
- Changes in the rate of cardiometabolic and pulmonary events during the COVID-19 pandemic
- Short report: Ethnicity and COVID-19 death in the early part of the COVID-19 second wave in England
- Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19
- HIV infection and COVID-19 death
- Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality
- Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
- Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids